27 results about "Orotic acid" patented technology

To provide pharmaceutical combinations of treating a clinical condition, e.g., AML.SOLUTION: A pharmaceutical combination comprising a DHODH inhibitor and an anti-CD38 therapeutic agent such as an anti-CD38 antibody is administered to a subject. The pharmaceutical combination can further comprise one or more additional therapeutic agents.SELECTED DRAWING: Figure 2D

The invention relates to the technical field of medicinal chemistry, in particular to salt of a dihydroorotate dehydrogenase inhibitor as well as a preparation method and application of the salt. The salt of the dihydroorotate dehydrogenase inhibitor is a salt of a compound as shown in a formula (I), the salt is sulfate or hydrochloride. Compared with the compound shown in the formula (I), the salt of the compound shown in the formula (I) has better solubility and bioavailability, and has excellent stability.

Provided herein are p-carboline compounds of formula (I) [0537], or forms thereof, and uses thereof to inhibit dihydroorotate dehydrogenase (DHODH), wherein R1, R2, R3, R4 and R5 are as defined herein. (I)

Disclosed herein are compounds, i.e., 6-substituted-2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of various disorders and diseases in which inhibition of DHODH is clinically useful, including cancers such as hematological cancers, including acute myeloid leukemia (AML), graft-versus-host disease, autoimmune disorders, and disorders associated with T-cell proliferation. The disclosed compounds may exhibit flip-flop kinetics when orally administered, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of excretion, governs the pharmacokinetics. The disclosed compounds may exhibit a sustained pharmacokinetic profile instead of an immediate-release profile. This Abstract is intended as a scanning tool for purposes of searching within a particular technical field and is not intended to limit the disclosure.

The invention discloses a zinc-orotic acid complex crystal material as well as a preparation method and fluorescent recognition application thereof. The chemical formula of the complex is [Zn2 (HOA) 2 (1, 3-dpp) (H2O) 2] n, and the complex has a 2-heavy interspersed two-dimensional network structure. The preparation method comprises the following steps: respectively preparing orotic acid, potassium hydroxide and zinc acetate into solutions, mixing the solutions with 1, 3-bis (4-pyridyl) propane and water, and carrying out ultrasonic treatment and heating treatment to obtain the crystal. The material has characteristic fluorescence emission at 370 nm, the intensity of the material can be obviously changed when encountering a specific substance, and the material can be used as a fluorescence sensing material to identify solvents such as methanol, DMSO, water and the like, specifically detect Fe < 3 + > ions, identify antibiotics dimethylaminotetracycline hydrochloride, furacilin and nitrofurantoin, identify a drug curcumin, and can be used as a fluorescent sensing material. And identifying food additives potassium sorbate and sodium benzoate.

The application discloses a method for catalytically producing 5-fluorouracil and application, and belongs to the technical field of biology. The method uses 5-fluoroorotic acid as a substrate and orotidine-5'-phosphate decarboxylase as a catalyst to efficiently catalyze the synthesis of 5-fluorouracil. The catalytic efficiency is further improved by molecular modification of orotidine-5'-phosphate decarboxylase, the efficient and green production of 5-fluorouracil is realized, and the application of 5-fluorouracil in the fields of medicine and the like is promoted.

To provide a food composition containing equol and an organic acid and having improved flavor, especially aroma.SOLUTION: The food composition contains an organic acid and equol, particularly at least one organic acid selected from the group consisting of carbonic acid, hydrogen carbonate, citric acid, lactic acid, phosphoric acid, gluconic acid, acetic acid, malic acid, orotic acid, ammonium salts thereof, alkali metal salts thereof, alkaline earth metal salts thereof, and chelates thereof, and equol.SELECTED DRAWING: None

The application relates to the technical field of veterinary traditional Chinese medicines, in particular to an anticoccidial combined extract, an anticoccidial composite additive and a preparation method and application thereof, and an anticoccidial product. The anticoccidial combined extract contains Terminalia chebula extract and Saussurea costus extract in a specific mass ratio, has a remarkable anticoccidial effect without other components, can significantly inhibit the activity of dihydroorotate dehydrogenase (DHODH), improve an anticoccidial index (ACI), reduce the oocyst production of coccidia, and reduce the degree of intestinal lesions of chickens caused by coccidia; meanwhile, the anticoccidial combined extract can significantly improve the daily weight gain and daily feed intake of broilers, reduce the feed-meat ratio, and has a double effect of “disease prevention + yield increase”.

The application belongs to the technical field of enzyme engineering, and discloses application of dihydroorotase in reducing purine content. Under specific reaction conditions, dihydroorotase can realize degradation of guanine. The reaction conditions include reaction pH, reaction temperature, and types and concentrations of catalysts. When it is applied to guanine degradation, the reaction pH is 7.0-10.0, the catalyst is a metal ion (Zn 2+ ), the concentration is 0.05-5 mM, and the reaction temperature is 20-45 DEG C. Catalytic reaction of purine substrates by the enzyme reaction conditions provided in the application can realize degradation of guanine, and the application lays a foundation for enzymatic preparation of low-purine food.

This application relates to the field of metabolic engineering and genetic engineering technology for production, specifically providing a uracil-producing strain, its construction method, and its application. This strain is... E. coli Knockout of the uridine kinase gene in the W3110 genome udk Simultaneously integrates the T7 RNA polymerase gene; weakens the uridine kinase gene. pyrH Overexpression of carbamoyl phosphate synthase gene carAB ribose-phosphokinase gene prsA pyrimidine-5'-nucleotide nuclease gene ppnN UMP phosphohydrolase gene umpH and umpG Ribonucleotide hydrolase 1 gene rihA and glutamine synthase gene glnA Heterogeneous introduction of wild-type Bacillus subtilis B. subtilis 168 orotate nucleoside monophosphate decarboxylase gene pyrF and orotic acid ribosyltransferase gene pyrE To achieve safe, efficient, and low-cost production of uracil.

Disclosed is compositions including L-carnitine and orotic acid and glyceryl phosphoryl ethanolamine for use in prevention of oxidative stress of cells. The compositions are also suitable for use in preventing and / or correcting neurodegenerative damages in a subject suffering from one Parkinson disease, Huntington disease and Alzheimer disease. Also disclosed is a colostrum-based dietary supplement enriched with L-carnitine and orotic acid and glyceryl phosphoryl ethanolamine.

An object of the present invention is to provide a compound useful as an anti-tumor agent or the like; an intermediate thereof; and a pharmaceutical composition, an anti-tumor agent, and a dihydroorotate dehydrogenase inhibitor, each of which contains the compound. According to the present invention, there is provided a compound represented by General Formula (1) or a salt thereof:in the formula, Z1, Z2, and Z3 are the same as or different from each other and represent a nitrogen atom or CH; Z4 represents a nitrogen atom or a general formula of CR6; Z5 represents a nitrogen atom or a general formula of CR7 provided that at least one of Z1, Z2, Z3, Z4, or Z5 represents a nitrogen atom; R1 represents a general formula of CONHR8 or the like; R2 represents a C3-8 cycloalkyl group which may be substituted or the like; R3, R5, R6, and R7 are the same as or different from each other and represent a hydrogen atom, a halogen atom, or the like; R4 represents an aryl group which may be substituted or a heterocyclic group which may be substituted; R8 represents a general formula of SO2R9 or the like; and R9 represents an amino group which may be protected or the like.

The application discloses a genetically engineered bacterium for improving the yield of mevalonic acid as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. In order to solve the technical problems of low carbon atom economy and limited theoretical yield of MVA biosynthesis technology, the application takes Escherichia coli as a starting strain, overexpresses a bifunctional acetaldehyde-ethanol dehydrogenase mutant AdhE A267T / E568K gene adhE mut , an acetyl-CoA acyltransferase / HMG-CoA reductase gene mvaE , an HMG-CoA synthetase gene mvaS , and introduces a tetracycline-induced CRISPRi system to inhibit the expression of an orotate-5'-phosphate decarboxylase gene pyrF , so that the carbon flux is led from the growth of the strain to the synthesis of mevalonic acid. The genetically engineered bacterium provided by the application can produce mevalonic acid by fermentation with ethanol as a carbon source, and the yield reaches 0.89 g / g. The application provides a new idea for improving the carbon atom economy of mevalonic acid biological manufacturing.

The present invention relates to 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and to a novel dosage regimen, as well as to their uses in the treatment of chronic inflammatory and / or autoimmune diseases. The compound of formula (I) mentioned inhibits dihydroorotate dehydrogenase (DHODH) and is known for the treatment and prevention of diseases, in particular its use in diseases in which there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

The application belongs to the technical field of screening of diagnostic markers for gestational diabetes, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application thereof. The application discloses a biomarker for predicting or diagnosing gestational diabetes, wherein the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrostercorol and cycloleucine, and more preferably comprises hypoxanthine, cortisol, dihydrostercorol, (3R, 4R)-D-erythrulose, creatine, cycloleucine and L-hydroxyproline. The seven biomarkers disclosed in the application can be used alone or in combination to predict or diagnose gestational diabetes in the early stage of pregnancy through plasma detection, effectively improve the early diagnosis rate of gestational diabetes, improve the prognosis of the disease, and have clinical use and promotion value.

The invention relates to the technical field of medicinal chemistry, in particular to salt of a dihydroorotate dehydrogenase inhibitor as well as a preparation method and application of the salt. The salt of the dihydroorotate dehydrogenase inhibitor is a salt of a compound as shown in a formula (I), the salt is hydrochloride, sulfate, hydrobromide or p-toluenesulfonate. Compared with the compound shown in the formula (I), the salt of the compound shown in the formula (I) has better solubility and bioavailability, and has excellent stability.

This invention discloses a zinc-orotic acid complex crystal material, its preparation method, and its fluorescence recognition application. The chemical formula of the complex is [Zn2(HOA)2(1,3-dpp)(H2O)2]. n It possesses a two-dimensional, double-interlaced network structure. Its preparation method involves preparing solutions of orotic acid, potassium hydroxide, and zinc acetate, mixing them with 1,3-bis(4-pyridyl)propane and water, and then subjecting the mixture to ultrasonic and heat treatment to obtain crystals. This material exhibits characteristic fluorescence emission at 370 nm, the intensity of which changes significantly upon contact with specific substances. This property can be utilized as a fluorescent sensing material to identify solvents such as methanol, DMSO, and water, and to specifically detect Fe. 3+ Ions that can identify antibiotics such as dimethylaminetetracycline hydrochloride, nitrofurazone, and nitrofurantoin; drugs such as curcumin; and food additives such as potassium sorbate and sodium benzoate.

The present invention refers to a 2-({3-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I)and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and / or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

The invention relates to the technical field of bio-based materials, and particularly discloses a composition containing orotic acid and a preparation method and application thereof, and the composition comprises the following components in parts by weight: 85.0-95.0 parts of orotic acid; 0.3 to 1.2 parts of microcrystalline cellulose; 0.05 to 1.5 parts of zinc oxide; 1.5 to 6.0 parts of epoxidized soybean oil; 0.05 to 0.8 part of vitamin E; and 2.0 to 7.0 parts of acetyl tributyl citrate. According to the invention, the auxiliary agent is added to be synergistically compounded with the orotic acid, so that the processing adaptability is successfully improved, and the melt flow rate is increased to meet the technological requirements of injection molding, tape casting and the like; the stability of the material is fundamentally improved, and the problem of caking during storage is solved; the material is endowed with composite functional characteristics, and the synergistic effect of static electricity resistance, ultraviolet resistance and oxidation resistance is achieved. Finally, a high-performance orotic acid-based material formula which is environment-friendly, biodegradable and suitable for high-added-value environment-friendly products is formed.

The invention relates to the technical field of food processing, and discloses a series of milk-flavored tofu based on whey sour slurry, which comprises soybean milk, raw milk and a coagulator, the coagulator is whey sour slurry, and a preparation method of the series of milk-flavored tofu based on whey sour slurry comprises the following steps: taking residual fresh whey after cheese (or cheese) preparation, inoculating lactic acid bacteria, fermenting at 30-37 DEG C for 12-48 hours until the pH value of the fermentation liquor is reduced to 3.5-4.5, and cooling to room temperature to obtain the series of milk-flavored tofu based on whey sour slurry. The addition amount of the raw milk is 15-50% of the total weight of the soybean milk, and when the addition amount of the raw milk is greater than 25%, the pH value of the whey sour slurry is preferably 3.5-4.0. According to the method, the sour slurry is prepared through whey fermentation to serve as a coagulator, high-value utilization of whey by-products is achieved, the bean curd can be endowed with natural frankincense flavor in the coagulation process, and the taste and the nutritional value of the product are improved. The method is suitable for the development of various bean curd products such as milk-flavored bean curd and meat paste nutritional bean curd, the variety and functionality of the bean curd products are expanded, and the requirements of different consumers can be met.

To provide alternative forms of compounds developed for treating conditions and diseases in which inhibition of dihydroorotate dehydrogenase (DHODH) would be beneficial.SOLUTION: Provided are various salts, including tris (hydroxymethyl) aminomethane salts and sodium salts, of a compound of the following formula, as well as various crystalline forms of a compound of the following formula, and pharmaceutical compositions comprising these salts and crystalline forms, methods of making the same.SELECTED DRAWING: None

The present invention relates to a novel salt compound of tegoprazan, which is a potassium-competitive acid blocker (P-CAB)-based drug, and a method for preparing same. The method according to the present invention can provide a novel tegoprazan orotate salt by using orotic acid, which is not harmful to the human body. In addition, through the preparation method of the present invention, it is possible to prepare a novel tegoprazan orotate salt with high purity (99.95% or greater) and properties similar to or superior to those of tegoprazan (e.g., the solubility of a tegoprazan orotate salt is 24 mg / mL whereas the solubility of tegoprazan is 3 mg / mL).

The invention belongs to the technical field of functional foods, and particularly relates to a preparation method and application of a functional food raw material lithium orotate containing trace element lithium. The preparation method provided by the invention comprises the following steps: dissolving orotic acid in ammonia water, filtering and removing impurities to obtain an orotic acid ammonia solution; dissolving a water-soluble lithium salt in water, filtering and removing impurities to obtain a lithium salt solution; and adding the lithium salt solution into the orotic acid ammonia solution, reacting, and filtering, washing and drying the obtained precipitate to obtain the lithium orotate. The lithium orotate prepared by the preparation method provided by the invention is a product which does not contain heteroanions and is relatively high in purity.

The present invention relates to the use of compounds (I) where the variables are as defined in the claims and the description, for combatting dihydroorotate-dehydrogenase inhibitor-resistant phytopathogenic fungi, and to a method for combatting dihydroorotate-dehydrogenase inhibitor-resistant phytopathogenic fungi comprising treating the phytopathogenic fungi or the materials, plants, the soil or seeds that are infected or infested or are at risk of being infected or infested with said phytopathogenic fungi with at least one compound (I). The invention relates moreover to a mutated DHODH inhibitor resistant DHODH enzyme and to a nucleic acid molecule comprising at least one nucleotide sequence encoding a mutated DHODH enzyme.

The present disclosure provides salts of 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid. The present disclosure also provides pharmaceutical compositions comprising salts of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a salt of the invention.